Bright Minds Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bright Minds Biosciences (DRUG).

Price Target Range — 9 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$131Upside to Avg. PT+138.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	Wolfe Research	—	Initiate	Outperform	$150
Aug 19, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$145
Aug 17, 2026	BTIG	Thomas Shrader	Maintained	Buy	$147
Jun 1, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$145
May 20, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$190→$220
Apr 13, 2026	Jefferies	Andrew Tsai	Initiate	Buy	$145
Mar 30, 2026	BTIG	Thomas Shrader	Maintained	Buy	$147
Mar 4, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$115→$145
Feb 17, 2026	BTIG	Thomas Shrader	Maintained	Buy	$147
Jan 7, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$72→$147
Jan 6, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$72→$147
Jan 2, 2026	Chardan Capital	Rudy Li	Maintained	Buy	$80
Dec 30, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$115
Sep 15, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$85
Sep 8, 2025	BTIG	Thomas Shrader	Initiate	Buy	$72
Aug 19, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$85
Jul 2, 2025	Cantor Fitzgerald	Pete Stavropoulos	Assumes	Overweight	—
May 21, 2025	Chardan Capital	Rudy Li	Maintained	Buy	$80
May 13, 2025	TD Cowen	Joseph Thome	Initiate	Buy	—
May 7, 2025	Chardan Capital	Rudy Li	Initiate	Buy	$80

Analyst Ratings News

PRO
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

Wolfe Research initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.

Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.

Benzinga Newsdesk

Bright Minds Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Bright Minds Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PRO
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

PRO
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

People Also Watch

People Also Watch

Bright Minds Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Bright Minds Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

PROHC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PROBTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

PROHC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PROPiper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

PROJefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

People Also Watch

People Also Watch

PRO
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

PRO
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

PRO
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145